Eyebright Medical Technology

Eyebright Medical Technology

Eyebright Medical Technology was founded in 2010 by Dr. Jiangbing Xie, an ophthalmologist who retains roughly a 13% stake as Chairman and CEO. The Beijing-based company designs and manufactures a broad portfolio of ophthalmic products — surgical implants, instruments, equipment, optometric lenses, and eye drops — and sells them into a healthcare system grappling with one of the world's highest myopia rates. Its listing on the Shanghai Stock Exchange provides a public-currency lens on a firm that operates more like an integrated platform than a pure medical-device original equipment manufacturer. Eyebright's product strategy covers the clinical continuum. On the surgical side, it produces intraocular lenses and related instruments for cataract and refractive procedures. On the consumer and diagnostic side, it offers contact lenses, optometric equipment, and, more recently, automated retail through a partnership with Meituan Health that launched 24-hour smart contact-lens stores in China. Research is anchored by a strategic collaboration with The Hong Kong Polytechnic University, a relationship focused on clinical translation, R&D, and talent development. The firm's geographic base is concentrated in Greater China, with commercial presence in Beijing and a Hong Kong international headquarters, and a global patent portfolio signaling ambitions beyond its domestic market. Early institutional backing came from Eight Roads Ventures, the investment arm of Fidelity International, which participated before the company's public listing. Beyond Dr. Xie, major shareholders include individual investor Lipin Mao (approximately 8.6%) and Beijing Bojiang Hechuang Technology Co., Ltd. (approximately 5.8%). The company runs a modest philanthropic initiative, "Bright Eyes for 100 People Public Welfare Action," consistent with the founder's clinical background. Most recently, Eyebright has been scaling its consumer-facing smart retail channels in partnership with China's large digital health platforms. Eyebright's structural differentiator is vertical integration within the Chinese ophthalmology market. It is not a conglomerate diversifying across healthcare sectors nor a pure venture portfolio — it is a publicly listed operating company whose R&D relationships, manufacturing scale, and direct-to-consumer retail experiments are all contained within a single eye-care vertical. That makes it a concentrated, albeit liquid, bet on China's growing demand for vision correction and surgical eye procedures, with governance resting squarely with a founder-ophthalmologist who controls the company's strategic direction.